GleamWall
中文EN

CURX Curanex Pharmaceuticals Inc

Pharmaceutical Preparations · Nasdaq · SEC CIK 2025942 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-850.0%
TTM EPS YoY-509.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-146.5%
ROA-140.3%
ROIC (approx.)-207.7%
Asset turnover—

Leverage & solvency

Liabilities / assets17.8%
Debt / equity0.00x
Current ratio17.84x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.34x
Accruals ratio-91.9%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$1.95M$2.59M$2.26M$2.31M$677,474———
SG&A expense$877,121$731,843$927,197$786,340$273,853$57,658$137,452$72,690
Operating income-$2.83M-$3.33M-$3.18M-$3.09M-$951,327-$57,658-$137,452-$147,366
Interest expense———$0$4,090$3,091$1,356—
Net income-$2.82M-$3.29M-$3.15M-$3.07M-$954,059-$60,346-$137,583-$145,939
EPS (basic)-1.86-0.12-0.11—-0.750.00-0.01—
EPS (diluted)-1.86-0.12-0.11—-0.750.00-0.01—
Weighted avg. shares (diluted)1.52M28.36M28.34M—1.28M24.00M24.00M—
Balance sheet
Cash & equivalents$1.58M$2.94M$4.00M$4.97M$5.80M$108,862—$148,891
Current assets$2.56M$4.79M$8.09M$11.23M$14.42M$711,337—$517,935
Total assets$3.10M$5.07M$8.41M$11.58M$14.48M$787,174—$517,935
Current liabilities$143,300$104,306$128,734$137,030$185,955$75,927—$14,575
Total liabilities$551,831$286,254$332,644$361,040$185,955$481,743—$14,575
Shareholders' equity$2.55M$4.79M$8.08M$11.22M$14.29M$305,431$365,777$503,360
Shares outstanding1.57M28.36M28.36M1.42M28.34M24.00M—1.20M
Cash flow statement
Operating cash flow-$1.36M-$1.08M-$954,560-$857,404-$9.19M-$290,081-$149,948-$95,427
Financing cash flow———$0$14.91M$200,000$200,000$0
Stock-based compensation$154,009$0$9,792—————

Free plan shows the latest 8 periods; Pro shows all 11 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.